A study of J. Garcia-Donas regarding the outcome of sunitinib treatment in advanced ccRCC found that PDGFRB was associated with better response evaluation criteria in solid tumours (RECIST) objective response to sunitinib19. This evidence concerns the gene PDGFRB and nonpapillary renal cell carcinoma.